Christopher Hess, MD
Neurology · Gainesville, FLNPI 1881848836
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,800 of the $9,220 with a category attached, or 95.4%. 7 manufacturers reported payments, led by Tanabe Pharma America, Inc. at 47.7% of the total. Reporting peaked in 2024 at $4,634 and has fallen 99.2% since, to $39 in 2025.
Across 17 payments — averaging $542.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$4K
- Saluda Medical Americas, Inc.$4K
- Mentor Worldwide LLC$246
- AbbVie$89
- Boston Scientific$32
- Merz North America, Inc.$31
- plus $22 from 1 others
What the payments were for
- Consulting fees$8,80095%
- Food & beverage$3314%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 1 | $4,400 |
| Saluda Medical Americas, Inc. | 2 | $4,400 |
| Mentor Worldwide LLC | 7 | $246 |
| AbbVie | 2 | $89 |
| Boston Scientific | 2 | $32 |
| Merz North America, Inc. | 2 | $31 |
| Medtronic | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$4,400
How this compares
$9,220 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 99 | $6,405 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 45 | $2,362 |
| Rasagiline Mesylate | 11 | $1,693 |
| AmantadineAmantadine Hcl | 27 | $1,186 |
| Primidone | 18 | $795 |
| Donepezil Hcl | 15 | $234 |
| Clonazepam | 18 | $157 |
Paid to pharmacies, not to this prescriber.
Other neurology in Gainesville
- Adolfo Ramirez ZamoraGainesville$363K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.